GLP-1 Market Rivalry: Eli Lilly and Novo Nordisk Battle for Weight-Loss Dominance

The global market for GLP-1 weight-loss medications is evolving into a high-stakes duopoly between Eli Lilly (LLY) and Novo Nordisk (NVO), with analysts forecasting the sector will approach a $100 billion valuation by the end of the decade. Novo Nordisk established an early lead with the commercialization of semaglutide, marketed as Ozempic for diabetes and Wegovy for weight loss. To maintain its edge, Novo recently secured approval for an oral version of Wegovy. Early data suggests this pill is expanding the patient base, with over 36% of oral Wegovy users being new to GLP-1 therapies. Eli Lilly has aggressively challenged this position with tirzepatide, sold as Mounjaro and Zepbound. By investing heavily in manufacturing capacity and demonstrating superior weight loss results in head-to-head studies, Lilly has captured approximately 60% of the U.S. market. The financial impact for Lilly has been substantial, with Mounjaro and Zepbound generating over $36 billion in combined revenue last year. Lilly is now further expanding its portfolio with the approval of Foundayo, its own oral weight-loss offering, which will compete directly with Novo's oral product. From a valuation perspective, Eli Lilly's stock currently trades at a significant premium compared to Novo Nordisk. Investors are now weighing Lilly's dominant U.S. market share and revenue growth against Novo's potentially more attractive entry price and early lead in the oral drug segment.